NCT00072475 · REGISTRY CONDITION SEARCH

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2016-08-01

RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Response

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Time to Transformation to AML

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Diagnosis of primary or secondary (therapy-related) myelodysplastic syndromes\* (MDS), including the following cellular types: * Refractory anemia (RA)\*\* * RA with excess blasts (RAEB)-1 * RA with ringed sideroblasts\*\* * Refractory cytopenia with multilineage dysplasia * Refractory cytopenia with multilineage dysplasia with ringed sideroblasts\* * MDS-unclassified\*\* * MDS associated with isolated del (5q)\*\* * Chronic myelomonocytic leukemia (CMML)-1 NOTE: \*High-risk MDS (i.e., RAEB-2 or CMML-2) is closed to accrual as of 11/30/06 NOTE: \*\*Accompanied with at least 1 of the following laboratory values: hemoglobin less than 10 g/dL, platelet count less than 50,000/mm3, or absolute neutrophil count less than 1,000/mm3 * No prior leukemia (i.e., 20% or greater blasts) * No prior primary or metastatic brain tumor or carcinomatous meningitis PATIENT CHARACTERISTICS: Age * 18 and over Performance status * WHO 0-2 Life expectancy * Not specified Hematopoietic * See Disease Characteristics Hepatic * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * AST no greater than 2.5 times ULN * APTT no greater than 1.5 times ULN * INR no greater than 1.5 Renal * Creatinine no greater than 1.5 times ULN * Urine protein negative by urinalysis * Protein 1+ by dipstick allowed provided total urine protein no greater than 500 mg AND creatinine clearance at least 50 mL/min by 24-hour urine collection Cardiovascular * No significant cardiac or vascular events within the past 6 months, including any of the following: * Acute myocardial infarction * Unstable angina * Uncontrolled hypertension * Severe peripheral vascular disease (e.g., ischemic pain at rest or nonhealing ulcers or wounds) * New York Heart Association class II-IV congestive heart failure * Cardiac arrhythmia * Disseminated intravascular coagulation or other coagulopathies * Deep vein or arterial thrombosis * No history of congenital long QTc syndrome or elongated QTc (\> 450 msec for males or 470 for females) Pulmonary * No pulmonary embolism within the past 6 months Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception during and for at least 3 months after study participation * No need for full anticoagulation within the past 6 months * No significant hemorrhage (e.g., visceral, gastrointestinal, genitourinary, or gynecological) requiring red blood cell transfusion within the past month * No known cerebral aneurysms, other cerebrovascular malformations, or CNS bleeding * No unhealed fractures, wounds, or ulcers PRIOR CONCURRENT THERAPY: Biologic therapy * More than 12 months since prior autologous stem cell or allogeneic transplantation * More than 6 months since prior antiangiogenic agents * More than 1 month since prior interferon for MDS * More than 1 month since prior hematopoietic growth factors for MDS * More than 1 month since prior epoetin alfa (EPO) for MDS * More than 1 month since prior thalidomide for MDS * More than 1 month since prior immunotherapy for MDS * No concurrent prophylactic growth factors or cytokines (e.g., filgrastim \[G-CSF\], sargramostim \[GM-CSF\], EPO or EPO-derivatives, or interleukin-11) Chemotherapy * No prior low-dose antimetabolites for MDS (e.g., hydroxyurea, azacitidine, or low-dose cytarabine) * More than 12 months since prior chemotherapy for another disease\* NOTE: \*Not MDS or leukemia Endocrine therapy * More than 1 month since prior corticosteroids for MDS * More than 1 month since prior androgens for MDS Radiotherapy * More than 12 months since prior radiotherapy for another disease\* NOTE: \*Not MDS or leukemia Surgery * More than 1 month since prior surgery, including needle biopsy of visceral organs and recovered * Bone marrow biopsy allowed * More than 2 weeks since prior placement of a subcutaneous or tunneled venous access device (e.g., PortaCath or Hickman's catheter) and adequately healed Other * No prior cytotoxic therapy for MDS * More than 1 month since prior administration of any of the following medications for MDS: * Danazol * Retinoids * Amifostine * Investigational agents * No concurrent administration of any of the following medications: * Warfarin * Heparin * Derivatives of heparin * Other anticoagulants * No concurrent grapefruit or grapefruit juice
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Adult patients with MDS receive treatment with vatalanib.
intervention Names
Drug: vatalanib
label
Vatalanib
type
EXPERIMENTAL

interventions

arm Group Labels
Vatalanib
description
Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
name
vatalanib
other Names
PTK787/ZK 222584
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 155
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Response was measured by International Standardized Response Criteria for MDS * Complete Response: Bone marrow showing \< 5% myeloblasts with normal maturation of all cell lines; Hgb \> 11 g/dL (untransfused), ANC ≥1.5 K/L, PLT ≥ 100 K/L, No blasts, no dysplasia * Partial remission: All of the CR criteria (if abnormal at baseline), except BM evaluation. Blasts decreased by ≥ 50% over baseline. Cellularity and morphology are not relevant. Hematologic improvement: * Erythroid (HI-E): For participants with baseline HGB \< 11g/dL, Major: \> 2g/dL increase, transfusion independence. Minor: 1-2g/dL increase, ≥ 50% decrease in transfusion requirements * Platelet (HI-P): For participants with baseline PLT \< 100 K/L: Major: absolute increase of \> 30 K/L, transfusion independence. Minor: ≥ 50% increase (net increase of \>10 K/L) * Neutrophil (HI-N): For participants with baseline ANC \< 1.5 K/L, Major: \> 100% increase (net increase \> 0.5 K/L). Minor: \> 100% increase (absolute increase \< 0.5 K/L)
measure
Number of Participants With Response
time Frame
Duration of study (up to 5 years)
description
Time to transformation to AML is defined as the time from registration to the transformation of MDS to AML or death of any cause. Participants not meeting these criteria were censored at the date of last follow-up. This outcome was estimated using the Kaplan Meier method.
measure
Time to Transformation to AML
time Frame
Duration of study (up to 5 years)

secondary Outcomes

description
Duration of response (DOR) was defined as the time from response (complete remission, partial remission or hematologic improvement) to progression or death of any cause. Responding and alive patients were censored at the date of last follow-up. The median DOR with 95% CI was estimated using the Kaplan Meier method. Response was measured by International Standardized Response Criteria for MDS (described in above outcome measure).
measure
Duration of Response
time Frame
5 yrs
description
Overall survival (OS) as the interval from the on-study date until death. OS was estimated using the Kaplan Meier method.
measure
Overall Survival
time Frame
Duration of study (up to 5 years)
description
Progression free survival (PFS) was defined as the time from registration to progression or death of any cause. Progression free and alive patients were censored at the date of last clinical assessment. The median PFS with 95% CI was estimated using the Kaplan Meier method. Progression is defined as * For patients with \<5% bone marrow blasts: ≥50% increase in blasts to \>5% blasts * For patients with 5-10% bone marrow blasts: ≥50% increase to \>10% blasts * For patients with 10-19% bone marrow blasts: increase to ≥20% blasts * One or more of the following: 50% or greater decrement from maximum remission/response levels in ANC \< 1.5 K/L or PLT\< 100 K/L, or reduction in HGB by at least 2 g/dL or becoming transfusion dependent Progression after HI: Includes one or more of the following * Decrement of 50% or greater from maximum response levels in ANC \< 1.5 K/L or PLT \< 100 K/L * Reduction in HGB concentration by at least 2 g/dL * Becoming transfusion dependent
measure
Progression-free Survival
time Frame
Duration of study (up to 5 years)

Full study description

brief Summary: RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes.
detailed Description: OBJECTIVES: Primary * Determine the response rate, in terms of hematologic improvement and complete and partial remission, in patients with primary or secondary (therapy-related) myelodysplastic syndromes treated with vatalanib. * Determine the time to transformation to acute myeloid leukemia (at least 20% blasts) or death in patients treated with this drug. Secondary * Determine the safety of this drug in these patients. * Determine the duration of response in patients treated with this drug. * Determine the cytogenetic response rate in patients treated with this drug. * Determine the overall and progression-free survival of patients treated with this drug. * Determine the incidence of infections requiring antibiotics or hospitalization or bleeding requiring red blood cell transfusions in patients treated with this drug. OUTLINE: This is a multicenter study. Patients are stratified\* according to risk group (low grade \[refractory anemia with or without ringed sideroblasts, refractory anemia with excess blasts-1, refractory cytopenia with multilineage dysplasia with or without ringed sideroblasts, myelodysplastic syndromes-unclassified, or chronic myelomonocytic leukemia-1\] vs high grade \[refractory anemia with excess blasts-2 or chronic myelomonocytic leukemia-2\]). NOTE: \*Stratification according to risk (low vs high) does not occur after 11/30/06. Patients receive oral vatalanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 6 additional courses after documentation of a CR. Patients are followed periodically for up to 5 years from study entry. PROJECTED ACCRUAL: Approximately 144 patients will be accrued for this study within 2.5 years.

Source references

references

citation
Gupta P, Miller AA, Owzar K, et al.: Pharmacokinetics of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B study 10105. [Abstract] J Clin Oncol 24 (Suppl 18): A-6573, 355s, 2006.
type
RESULT
citation
Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA; Alliance for Clinical Trials in Oncology. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct;31(5):1311-20. doi: 10.1007/s10637-013-9978-z. Epub 2013 May 23.
pmid
23700288
type
RESULT

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-697668bf50117ccafb0f
requested nct id
NCT00072475
primary nct id
NCT00072475
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
payload sha256
440de792ab7350c3bf5ef8e750d9e2587f64141acd4eaac01f24540e083a5fbd
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-697668bf50117ccafb0f
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00072475
occurrences
context exact
NCT00072475
end
11
exact text
NCT00072475
start
0
offset unit
unicode_code_points
query cond
Juvenile Myelomonocytic Leukemia
query disease state id
ds-juvenile-myelomonocytic-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
source file sha256
cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
source json pointer
/studies/142/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
316cd15af76dfffb37da488173d08e553867f0f1dd4cc44ad224c072f9e1a7d4
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Juvenile+Myelomonocytic+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice